ALTEOGEN Inc. (196170)

Overview

ALTEOGEN Inc. is a biopharmaceutical company with a primary focus on the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. Founded in 2008 and headquartered in Daejeon, South Korea, ALTEOGEN is at the forefront of innovative treatments for various medical conditions. The company leverages its proprietary technologies, NexP for long-acting therapeutics and NexMab for antibody-drug conjugates (ADC), to develop its pipeline of products. Through strategic alliances with companies such as Kissei Pharmaceutical and Cristalia, ALTEOGEN is expanding its global footprint and accelerating the development of critical therapeutics.

Products and Services

• ALT-P1

  An advanced formulation of long-acting human growth hormone currently in Phase IIa clinical trial. ALT-P1 aims to enhance patient compliance and effectiveness in treating growth hormone deficiency with its prolonged action.

• ALT-Q2

  A long-acting active form of coagulation factor VIIa designed for hemophilia treatment, based on ALTEOGEN's NexP technology. ALT-Q2 is aimed at reducing bleeding episodes in individuals with hemophilia by providing a longer-lasting treatment option.

• ALT-P7

  This product is a targeted therapy for breast and gastric cancer, in Phase I clinical trial. ALT-P7 utilizes ALTEOGEN's technology to specifically target cancer cells, potentially offering a more effective and less toxic treatment option.

• ALT-Q5

  An antibody-drug conjugate (ADC) utilizing NexMab ADC technology, in development for the treatment of ovarian cancer. ALT-Q5 represents ALTEOGEN's effort to bring forth innovative cancer treatments by combining targeted antibodies with potent cancer-killing agents.

• ALT-LS2

  A subcutaneous formulation of trastuzumab (Herceptin) for breast and gastric cancer treatment. ALT-LS2 aims to improve patient experience by enabling home administration and reducing the frequency of hospital visits.

• ALT-L9

  In collaboration with Kissei Pharmaceutical, this biosimilar of Eylea (Aflibercept) is under Phase 1 clinical trial. ALT-L9 is part of ALTEOGEN's strategic efforts to expand its product range into biosimilars, targeting eye diseases such as wet age-related macular degeneration.

• ALT-L2

  Another strategic development in partnership with Cristalia is the Phase II clinical trial of ALT-L2, a biosimilar of Herceptin (Trastuzumab). This monoclonal antibody targets breast cancer treatment, reinforcing ALTEOGEN's commitment to offering more accessible cancer care solutions.